Thermo Fisher Scientific delivered robust Q2 financial results, beating revenue and earnings expectations, prompting an 11% stock surge. Revised full-year guidance includes higher revenue and adjusted EPS, buoyed by active cost-cutting and easing tariff tensions. Similarly, Lonza and Samsung Biologics reported revenue growth despite headwinds such as client funding cuts and tariffs. These earnings attest to the resilience and strategic agility of contract development and manufacturing organizations (CDMOs) in a challenging macroeconomic landscape.